Leading International Investment Research

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Leading International Investment Research, Edison Investment Research

Equity Bottom-Up

Symbio Pharmaceuticals / Equity Bottom-Up

<p>SymBio announced on 23 September 2020 that it has received approval from the PMDA for the ready-to-dilute (RTD) formulation of Treakisym (bendamustine) in Japan. This formulation, licensed from Eagle Pharmaceuticals, is part of SymBio’s pipeline management strategy and the company has exclusivity on the formulation until 2031. The company intends to begin marketing the product in January 2021.</p>

SymBio announced on 23 September 2020 that it has received approval from the PMDA for the ready-to-dilute (RTD) formulation of Treakisym (bendamustine) in Japan. This formulation, licensed from Eagle Pharmaceuticals, is part of SymBio’s pipeline management strategy and the company has exclusivity on the formulation until 2031. The company intends to begin marketing the product in January 2021.

SymBio Pharmaceuticals - Treakisym RTD approved